Cover Image
市場調查報告書

轉移性葡萄膜黑色素瘤的開發中產品分析

Metastatic Uveal Melanoma - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 305183
出版日期 內容資訊 英文 56 Pages
訂單完成後即時交付
價格
Back to Top
轉移性葡萄膜黑色素瘤的開發中產品分析 Metastatic Uveal Melanoma - Pipeline Review, H2 2016
出版日期: 2016年12月30日 內容資訊: 英文 56 Pages
簡介

所謂轉移性葡萄膜黑色素瘤是指由眼球(葡萄膜)發病,並轉移到人體其他部位的癌症。最常轉移到肝臟,其他肺、骨、皮下也很常見。主要的症狀為黃疸和皮膚的發癢·皮疹、肝臟內部酵素的異常增加、腹痛、食慾不振、噁心·嘔吐等。主要的治療方法有外科手術和化療、放射治療等。

本報告提供全球各國治療轉移性葡萄膜黑色素瘤用的開發中產品開發情形相關分析,彙整產品開發·上市的最新趨勢,及臨床實驗各階段的產品一覽,再加上主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

轉移性葡萄膜黑色素瘤概要

治療藥的開發

  • 轉移性葡萄膜黑色素瘤開發中產品:概要
  • 轉移性葡萄膜黑色素瘤開發中產品:比較分析

各企業開發中的轉移性葡萄膜黑色素瘤治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品

轉移性葡萄膜黑色素瘤治療藥:開發中的產品一覽(各企業)

轉移性葡萄膜黑色素瘤治療藥的開發企業

  • AstraZeneca PLC
  • Eli Lilly and Company
  • Novartis AG
  • Pfizer Inc.
  • Spectrum Pharmaceuticals, Inc.

轉移性葡萄膜黑色素瘤:治療藥的評估

  • 單劑治療藥的情況
  • 標的
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • selumetinib sulfate
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • sunitinib malate
  • vincristine sulfate liposomal
  • LY-2801653
  • sotrastaurin acetate
  • MEK-162

轉移性葡萄膜黑色素瘤治療藥:開發中產品的最新趨勢

轉移性葡萄膜黑色素瘤治療藥:暫停開發的產品

轉移性葡萄膜黑色素瘤的相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿(全2件)

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8909IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Metastatic Uveal Melanoma - Pipeline Review, H2 2016, provides an overview of the Metastatic Uveal Melanoma (Oncology) pipeline landscape.

Metastatic uveal melanoma is a cancer that has spread from the eye (uveal) to other parts of the body. The most common site of metastasis for uveal melanoma is the liver. Other common sites of metastasis include the lung, bones and just beneath the skin (subcutaneous). Symptoms include jaundice, itchy skin or rash, abnormally high enzymes in the liver, abdominal pain, appetite loss, nausea, and vomiting. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Metastatic Uveal Melanoma - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Metastatic Uveal Melanoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Metastatic Uveal Melanoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Metastatic Uveal Melanoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and IND/CTA Filed stages are 3, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Metastatic Uveal Melanoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Metastatic Uveal Melanoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Metastatic Uveal Melanoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Metastatic Uveal Melanoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Metastatic Uveal Melanoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Metastatic Uveal Melanoma (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Metastatic Uveal Melanoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Metastatic Uveal Melanoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Metastatic Uveal Melanoma Overview
  • Therapeutics Development
    • Pipeline Products for Metastatic Uveal Melanoma - Overview
    • Pipeline Products for Metastatic Uveal Melanoma - Comparative Analysis
  • Metastatic Uveal Melanoma - Therapeutics under Development by Companies
  • Metastatic Uveal Melanoma - Therapeutics under Investigation by Universities/Institutes
  • Metastatic Uveal Melanoma - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Metastatic Uveal Melanoma - Products under Development by Companies
  • Metastatic Uveal Melanoma - Products under Investigation by Universities/Institutes
  • Metastatic Uveal Melanoma - Companies Involved in Therapeutics Development
    • Bellicum Pharmaceuticals Inc
    • Celldex Therapeutics Inc
    • Eli Lilly and Company
    • Novartis AG
    • Spectrum Pharmaceuticals Inc
  • Metastatic Uveal Melanoma - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • alpelisib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BPX-701 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • emibetuzumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • glembatumumab vedotin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KCN-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LXS-196 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • merestinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sotrastaurin acetate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vincristine sulfate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Metastatic Uveal Melanoma - Dormant Projects
  • Metastatic Uveal Melanoma - Discontinued Products
  • Metastatic Uveal Melanoma - Product Development Milestones
    • Featured News & Press Releases
      • Apr 18, 2016: Celldex Therapeutics Presents data on Glembatumumab Vedotin at AACR 2016
      • Jan 11, 2016: Bellicum Pharmaceuticals Announces Submission of BPX-701 Clinical Trial Protocols for Review by the NIH RAC
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Metastatic Uveal Melanoma, H2 2016
  • Number of Products under Development for Metastatic Uveal Melanoma - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Metastatic Uveal Melanoma - Pipeline by Bellicum Pharmaceuticals Inc, H2 2016
  • Metastatic Uveal Melanoma - Pipeline by Celldex Therapeutics Inc, H2 2016
  • Metastatic Uveal Melanoma - Pipeline by Eli Lilly and Company, H2 2016
  • Metastatic Uveal Melanoma - Pipeline by Novartis AG, H2 2016
  • Metastatic Uveal Melanoma - Pipeline by Spectrum Pharmaceuticals Inc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Metastatic Uveal Melanoma - Dormant Projects, H2 2016
  • Metastatic Uveal Melanoma - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Metastatic Uveal Melanoma, H2 2016
  • Number of Products under Development for Metastatic Uveal Melanoma - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top